

Patent Application
Attorney Docket No. PC11695A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:
BISHOP WLODECKI, ET AL.

APPLICATION NO.: 10/664,706

Examiner:

FILING DATE: SEPTEMBER 18, 2003

Group Art Unit: 1614

TITLE: QUINOLINE DERIVATIVES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).


Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445. A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: May 21, 2004


Jolene W. Appleman
Attorney for Applicant(s)
Reg. No. 35,428

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212)733-3552



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB number.

Approved for use through 04/30/2003. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small status. See 37 CFR 1.27

Total Amount of Payment (\$)**180.00**

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit
Account
Number

16-1445

Deposit
Account
Name

Pfizer Inc.

The Commissioner is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☐ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	
SUBTOTAL (1) (\$)					

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

		Extra Claims	Fee from below	Fee Paid
Total Claims		-20**=	X	=
Independent Claims		- 3**=	X	=
Multiple Dependent				=

** or number previously paid, if greater; For Reissues, see below

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	**Reissue independent claims over original patent
1205	18	2205	9	**Reissue claims in excess of 20 and over original patent
SUBTOTAL (2) (\$)				

Complete If Known

Application Number	10/664,706
Filing Date	SEPTEMBER 10, 2003
First Named Inventor	BISHOP WLODECKI
Examiner Name	NOT ASSIGNED
Art Unit	1614
Attorney Docket No.	PC11695A

FEE CALCULATION (continued)

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late fee or oath	
1052	50	2052	25	Surcharge-late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	400	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17 (q)	
1801	770	2801	365	Request for Continued Examination (RCE)	
1806	180	1806	180	Submission of Information Disclosure Statement	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	

Other Fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)**180.00**


SUBMITTED BY

Name (Printed/Type) Jolese W. Appleman
Signature

Date May 21, 2004

Complete (If Applicable)

Reg. Number 35,428
Telephone (212) 733-3552



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										ATTY. DOCKET NO. PC11695A		SERIAL NO. 10/664,706		
										APPLICANT BISHOP WLODECKI, et al.				
										FILING DATE SEPTEMBER 18, 2003		GROUP 1614		
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
		0	1	7	3	5	8	5	03/7/85	EP				N
			8	1	2	9	1	1	09/06/51	Dutch				N
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
		Diaz de Arce, Humberto; "Some Derivatives of 8-Bromo-6-methylquinoline", J. American Chemical Society, Vol. 72, 1950, pages 2971-2974; XP002273437												
		Manabe, Kei; "Receptors for Oxo Acids: Effects of Intra-Ion Pair Hydrogen Bonding on Acid-Base Equilibria", J. Org. Chem., Vol 58, 1993, pgs 6692-6700 XP-002273436												
		Steck, Edgar A.; "Quinolines. III. The Synthesis of 5- and 7-Chloro- and Bromo-3-methyl-4-dialkylaminoalkylaminoquinolines", J. American Chemical Society, Vol 68, 1946, pgs 380-383, XP-002273436												
		Alabaster, C. T., "2(1H)-Quinolines with Cardiac Stimulant Activity. 1. Synthesis and Biological Activities of (Six-Membered Heteroaryl)-Substituted Derivatives. J. Med. Chem., Vol. 31, 1988, pgs 2048-2056, XP-002273434												
		Davis, Steven E., "2,4-Diamino-5-benzylpyrimidines and Analogues as Antibacterial Agents. 11. Quinolylmethyl Analogues with Basic Substituents Conveying Specificity, J. Med. Chem, Vol. 32, 1989, pgs 1936-1942, XP-002273433												
		Jacobs, Christopher, "1-Imidazolyl(alkyl)-Substituted Di-and Tetrahydroquinolines and Analogues Syntheses and Evaluation of Dual Inhibitors of Thromboxane A2 Synthase and Aromatase" J. Med. Chem, Vol. 43, 2000, pgs 1841-1851, XP-002273432												
EXAMINER														
DATE CONSIDERED														
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE